Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer

Απλή σελίδα τεκμηρίου
dc.contributor.authorRazis, E.en
dc.contributor.authorDimopoulos, A. M.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorKalofonos, H.en
dc.contributor.authorBriassoulis, E.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorKeramopoulos, A.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:23:42Z
dc.date.available2015-11-24T19:23:42Z
dc.identifier.issn0735-7907-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22355
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/mortality/pathology/surgeryen
dc.subjectChemotherapy, Adjuvanten
dc.subjectConfidence Intervalsen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectDrug Administration Scheduleen
dc.subjectEpirubicin/administration & dosage/adverse effectsen
dc.subjectFemaleen
dc.subjectGreeceen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Metastasisen
dc.subjectPaclitaxel/administration & dosage/adverse effectsen
dc.subjectReceptors, Estrogen/analysisen
dc.subjectReceptors, Progesterone/analysisen
dc.subjectSurvival Analysisen
dc.titleDose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast canceren
heal.abstractThe purpose of this study was to evaluate the activity and toxicity profile of dose-dense sequential chemotherapy with epirubicin (EPI) and paclitaxel in advanced breast cancer (ABC). From January to September 1997, 41 patients with recurrent or metastatic (stage IV) breast cancer were enrolled in the study. Their median age was 57 (range, 33-77) years and median performance status 0 (range, 0-2). Twenty patients had received adjuvant chemotherapy. The chemotherapeutic regimen consisted of 4 cycles of EPI 110 mg/m2 every 2 weeks followed by 4 cycles of paclitaxel, 225 mg/m2 over 3 hours every 2 weeks. G-CSF was administered prophylactically on days 2-10 of each cycle. 34 (83.0%) patients completed all 8 cycles of chemotherapy. A total of 304 cycles were administered, 259 (85.0%) of them at full dose. Thirty (10.0%) cycles were delivered with a delay. The relative median dose intensities of EPI and paclitaxel were 0.95. Most common grade 3-4 side effects were anemia (15.0%) neutropenia (12.0%), thrombocytopenia (5.0%), nausea/vomiting (10.0%), febrile neutropenia (7.5%), and alopecia (90.0%). Overall, 8 (19.5%) patients achieved a complete and 15 (36.5%) a partial response. Median duration of response was 8.4 (range, 3.1-15.5+) months. After a median follow-up of 18.5 months, median time to progression was 8.7 (range, 0.5-21+) months; median survival has not been reached yet. Dose-dense sequential chemotherapy with EPI and paclitaxel shows promising activity as first-line treatment in ABC. Randomized studies comparing this type of chemotherapy with the classical administration of the two drugs together every 3 weeks are ongoing.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11296618-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.1081/CNV-100000148-
heal.journalNameCancer Investen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2001-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ